News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biogen Idec, Inc. (Massachusetts) (BIIB), Abbott Laboratories (ABT) Advance Daclizumab for Relapsing-Remitting Multiple Sclerosis; Biogen to Pay $30 Million in Advance



5/24/2010 10:30:26 AM

Boston Business Journal -- Biogen Idec Inc. will pay Abbott Laboratories $30 million to advance a new phase 3 trial for a drug candidate targeting multiple sclerosis. The two companies announced Monday that the study’s first patient had been enrolled.


Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES